gpx4  (Proteintech)

Journal: Journal of Bone Oncology

Article Title: Lapatinib induces ferroptosis in osteosarcoma via the SLC1A5-GPX4 axis

doi: 10.1016/j.jbo.2026.100771

Figure Lengend Snippet: The SLC1A5-GPX4 axis mediates lapatinib-induced ferroptosis. (A-B) Western blot analysis of SLC1A5 protein expression in OS cells treated with Lap or Lap+DFO (100 μM). (C) Evaluation of the interaction between Lap and SLC1A5 using CETSA. (D) DARTS assay confirming the interaction between Lap and SLC1A5. (E) Viability assessment by calcein-AM (live, green)/PI (dead, red) staining in cells overexpressing SLC1A5. (F) Detection of intracellular Fe 2+ by FerroOrange probe. (G-H) Measurements of Gln and GSH levels in OS cells under indicated conditions. (I) Western blot analysis of SLC1A5 and GPX4 expression following Lap treatment in SLC1A5-overexpressing cells. (J) Western blot analysis of SLC1A5 protein expression in OS cells transfected with control siRNA or siRNA SLC1A5, showing knockdown efficiency. (K) GPX4 protein expression after lapatinib treatment for 24 h in control and SLC1A5 knockdown cells. (L) Cell viability determined by CCK-8 assay. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Article Snippet: The membranes were blocked with 5% non-fat milk at room temperature for 1 h, then incubated overnight at 4 °C with primary antibodies against GPX4 (1:5000, Abmart, T56959 ), SLC1A5 (1:2500, Selleck, F0619), and β-actin (1:10000, Servicebio, GB11001).

Techniques: Western Blot, Expressing, Staining, Transfection, Control, Knockdown, CCK-8 Assay

Journal: Journal of Bone Oncology

Article Title: Lapatinib induces ferroptosis in osteosarcoma via the SLC1A5-GPX4 axis

doi: 10.1016/j.jbo.2026.100771

Figure Lengend Snippet: Lapatinib induces ferroptosis by suppressing GPX4. (A-B) Western blot analysis of GPX4 protein expression in OS cells following Lap treatment. (C—D) Western blot analysis of GPX4 expression in OS cells treated with Lap and DFO (100 μM). (E-F) Assessment of cell death by propidium iodide (PI) staining following GPX4 overexpression. (G-H) Measurement of intracellular ROS levels using DCFH-DA probe. (I-J) Flow cytometric analysis of lipid ROS using C11-BODIPY probe.

Article Snippet: The membranes were blocked with 5% non-fat milk at room temperature for 1 h, then incubated overnight at 4 °C with primary antibodies against GPX4 (1:5000, Abmart, T56959 ), SLC1A5 (1:2500, Selleck, F0619), and β-actin (1:10000, Servicebio, GB11001).

Techniques: Western Blot, Expressing, Staining, Over Expression

Journal: Journal of Bone Oncology

Article Title: Lapatinib induces ferroptosis in osteosarcoma via the SLC1A5-GPX4 axis

doi: 10.1016/j.jbo.2026.100771

Figure Lengend Snippet: Lapatinib suppresses tumor growth by activating ferroptosis in vivo. (A) Experimental timeline for in vivo administration of Lap (25 mg/kg, i.p., daily) and DFO (10 mg/kg, i.p., daily). (B—C) Representative photographs of resected xenograft tumors from each group ( n = 4) (Scale bar: 1 cm). (D-E) Tumor weight and volume at the study endpoint. (F-G) Curves depicting body weight changes and tumor growth over time. (H) Hematoxylin and eosin (H&E) staining and immunohistochemical (IHC) analysis of tumor sections (scale bar: 50 μm). (I) Western blot analysis of SLC1A5 and GPX4 protein levels in tumor tissues. (J-K) Measurement of GSH and MDA levels in mouse plasma.

Article Snippet: The membranes were blocked with 5% non-fat milk at room temperature for 1 h, then incubated overnight at 4 °C with primary antibodies against GPX4 (1:5000, Abmart, T56959 ), SLC1A5 (1:2500, Selleck, F0619), and β-actin (1:10000, Servicebio, GB11001).

Techniques: In Vivo, Staining, Immunohistochemical staining, Western Blot, Clinical Proteomics